WinSanTor (2019)
About this raise
Winsantor is here to make sure that no one suffers from peripheral neuropathy (PN). PN affects 1 in 15 people in the US, and it’s when the nerves die due to disease, injuries, cancer, or genetic diseases. There is currently no treatment -- just drugs that help reduce the pain. Winsantor, however, is currently in trials that show they be on track to reverse the disease, both biologically and functionally. So far, over $30M of non-dilutive funding has driven R&D; they are currently entering Phase 2 of early efficacy studies; and they aim to have their drug approved by 2021 to start helping -- and changing -- the lives of those who are affected.
Investment Overview
Invested : $596,649
Deal Terms
Total Commitments
- Platform
- Wefunder
- Start Date
- 09/28/2018
- Close Date
- 03/20/2019
$300,000
$1,070,000
$500
SAFE
Growth Stage
RegCF
$70,000,000
25%
Company & Team
Company
- Year Founded
- 2011
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Capital Intensity
- Location
- San Diego, California
- Company Website
-
Visit Website
Team
- Employees
- 8
Financials
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/29/2024 | Wefunder | $500,000,000 | $193,502 | SAFE | Funded | RegCF |
| 04/28/2020 | StartEngine | $75,000,000 | $32,651 | Convertible Note | Not Funded | RegCF |
| 03/20/2019 | Wefunder | $70,000,000 | $596,649 | SAFE | Funded | RegCF |